Overall, mono- and dual-incretin agonist therapies represent a significant advance in the treatment landscape of MASLD/MASH, although long-term outcome data are required to confirm durability, safety, and impact on major adverse liver-related outcomes.
INTRODUCTION
Metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis (MASLD/MASH) pharmacotherapy is changing rapidly after the approval of resmetirom and semaglutide for selected adults with noncirrhotic MASH and F2-F3 fibrosis; management must also address obesity...
M. M. Syed-Abdul· Expert Opinion on Pharmacoth...· 0 citations
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most prevalent and severe liver disease globally, encompassing a spectrum from isolated steatosis to metabolic dysfunction-associated steatohepatitis (MASH), the progressive inflammatory form that can lead to fibrosis, cirrhosis, and hepatocellular...
Dana A. Meije, A. Holleboom, S. V. D. van de Graaf· Biochemical Pharmacology· 0 citations
The prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) has risen substantially over recent decades, affecting an estimated 38% of the global population. It has become a leading cause of liver disease, with the potential to progress to steatohepatitis (MASH), fibrosis, and ultimately cirrhosi...
Jimena Soto-Campillo, M. García-Rodríguez, Norberto C. Chávez-Tapia· Metabolism and Target Organ...· 0 citations
Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by progressive fibrosis and an increased risk of hepatocellular carcinoma (HCC). Recently, approved drug treatments for MASLD, including thyroid hormone receptor beta (THR-β) and glucagon-like peptide-1 (GLP-1) receptor agonists, have bee...
Asha Z. Goodman, Winston T. Stauffer, Philippe Gallay· PLoS ONE· 0 citations
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the leading cause of chronic liver disease worldwide, driven by increasing obesity and type 2 diabetes mellitus. The expanding use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) raises an epidemiological question: could therapies targeting the...
Evelyn Nunes Goulart da Silva Pereira, Karine Lino Rodrigues· Frontiers in Endocrinology· 0 citations
Abstract Pediatric obesity and metabolic dysfunction‐associated steatotic liver disease (MASLD) prevalence has risen markedly over the past decade. Due to transition delays and workforce shortages, pediatric specialists often manage patients into young adulthood, and thus familiarity with adult pharmacotherapies for MA...
Brandon J. Perumpail, A. Tou, Jennifer Panganiban· JPGN Reports· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
